The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 237 of the 241 references it cites were found in a registry or an index.
Abstract
Objective: To develop clinical practice guidelines for the management of patients with primary aldosteronism. Participants: The Task Force included a chair, selected by the Clinical Guidelines Subcommittee of the Endocrine Society, six additional experts, a methodologist, and a medical writer. The guideline was cosponsored by American Heart Association, American Association of Endocrine Surgeons, European Society of Endocrinology, European Society of Hypertension, International Association of Endocrine Surgeons, International Society of Endocrinology, International Society of Hypertension, Japan Endocrine Society, and The Japanese Society of Hypertension. The Task Force received no corporate funding or remuneration. Evidence: We searched for systematic reviews and primary studies to formulate the key treatment and prevention recommendations. We used the Grading of Recommendations, Assessment, Development, and Evaluation group criteria to describe both the quality of evidence and the strength of recommendations. We used “recommend” for strong recommendations and “suggest” for weak recommendations. Consensus Process: We achieved consensus by collecting the best available evidence and conducting one group meeting, several conference calls, and multiple e-mail communications. With the help of a medical writer, the Endocrine Society's Clinical Guidelines Subcommittee, Clinical Affairs Core Committee, and Council successfully reviewed the drafts prepared by the Task Force. We placed the version approved by the Clinical Guidelines Subcommittee and Clinical Affairs Core Committee on the Endocrine Society's website for comments by members. At each stage of review, the Task Force received written comments and incorporated necessary changes. Conclusions: For high-risk groups of hypertensive patients and those with hypokalemia, we recommend case detection of primary aldosteronism by determining the aldosterone-renin ratio under standard conditions and recommend that a commonly used confirmatory test should confirm/exclude the condition. We recommend that all patients with primary aldosteronism undergo adrenal computed tomography as the initial study in subtype testing and to exclude adrenocortical carcinoma. We recommend that an experienced radiologist should establish/exclude unilateral primary aldosteronism using bilateral adrenal venous sampling, and if confirmed, this should optimally be treated by laparoscopic adrenalectomy. We recommend that patients with bilateral adrenal hyperplasia or those unsuitable for surgery should be treated primarily with a mineralocorticoid receptor antagonist.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Algorithm for the detection, confirmation, subtype testing, and treatment of PA. a We recommend unilateral laparoscopic adrenalectomy for patients with documented unilateral PA (ie, APA or UAH) (1 ⎪ QQQE ). If a patient is unable or unwilling to undergo surgery, we recommend medical treatment including a MR antagonist (1 ⎪ QQQE ). If an ARR-positive patient is unwilling or unable to undergo further investigations, we similarly recommend medical treatment including an MR antagonist (1 ⎪ QQEE ). b Instead of proceeding directly to subtype classification, we recommend that patients with a positive ARR undergo one or more confirmatory tests to definitively confirm or exclude the diagnosis (1 ⎪ QQEE ). However, in the setting of spontaneous hypokalemia, undetectable renin, and PAC > 20 ng/dL (550 pmol/L), we suggest that there may be no need for further confirmatory testing (2 ⎪ QEEE ). c We recommend that when surgical treatment is feasible and desired by the patient, an experienced radiologist should use AVS to make the distinction between unilateral and bilateral adrenal disease (1 ⎪ QQQE ). Younger patients ( < age 35) with spontaneous hypokalemia, marked aldosterone excess, and unilateral adrenal lesions with radiological features consistent with a cortical adenoma on adrenal CT scan may not need AVS before proceeding to unilateral adrenalectomy (2 ⎪ QEEE ). [Adapted from J. W. Funder et al: Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab . 2008;93:3266-3281 (3), with permission. © Endocrine Society.]](https://figures.cochat.ai/paper-figures/aaade82f5c4b425bbdee69e74321806d/the-management-of-primary-aldosteronism-case-detection-diagnosis-and-treatment-figure-1.png)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most common types of secondary hypertension in adults are renal parenchymal disease, renovascular hypertension, primary aldosteronism, chronic sleep apnea, and substance/drug-induced.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [116]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A specific cause of secondary hypertension can be identified in 5%-10% of hypertensive patients (Table 11).”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [116]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early diagnosis of secondary hypertension and the institution of appropriate targeted treatment have the potential to cure hypertension in some patients or improve BP control/reduce the number of prescribed antihypertensive medications in others.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [116]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypokalemia, which reduces aldosterone secretion, should be corrected with oral K+ supplements before testing.”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [289]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients with unilateral disease (50%; aldosterone-producing adenoma or, much less frequently, unilateral hyperplasia) respond to unilateral laparoscopic adrenalectomy with complete cure (≈50%) or improvement (≈50%) in BP control.”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [289]
Experimental — accuracy not yet measured
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation group, an international group with expertise in the development and implementation of evidence-based guidelines (2).”
MethodNational High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) · PEDIATRICS · doi:10.1542/peds.114.2.s2.555 · Cited by 6,938
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
(1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440420033005 · Cited by 3,777
(2003) · Journal of Hypertension · doi:10.1097/00004872-200311000-00002 · Cited by 2,672
Funder, J. W., Carey, R. M., Fardella, C., Gomez-Sanchez, C. E., Mantero, F., Stowasser, M., Young, W. F., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0104 · Cited by 1,554 · cited 3×
“The recommendations and suggestions made by the Task Force were subject to extensive consultation before being published in the Journal of Clinical Endocrinology and Metabolism in 2008 (3).”
MethodSelf-citationEvidence for an increased rate of cardiovascular events in patients with primary aldosteronism
Milliez, P., Girerd, X., Plouin, P.-F., Blacher, J., Safar, M. E., & Mourad, J.-J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.01.015 · Cited by 1,547 · cited 2×
“Several outcome studies also have provided evidence that PA patients are particularly at risk of cardiovascular/ renal complications, including arrhythmias, myocardial infarction, strokes, chronic kidney disease, and death, compared with age-, sex-, and BP-matched essential hypertensives (30, 33, 156).”
BackgroundResultA prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients
Rossi, G. P., Bernini, G., Caliumi, C., Desideri, G., Fabris, B., Ferri, C., Ganzaroli, C., Giacchetti, G., Letizia, C., Maccario, M., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.059 · Cited by 1,467 · cited 2×
“However, some groups have suggested that when clinicians administer a bolus injection of cosyntropin and sample the adrenal veins simultaneously, cosyntropin does not improve the diagnostic accuracy of AVS, and, in fact, cosyntropin may increase secretion from the nonadenomatous gland to a greater degree than from the…”
BackgroundSelf-citation
Research works printed but not linked: 3
- 15. Tucker RM, Labarthe DR. Frequency of surgical treatment for hypertensioninadultsattheMayoClinicfrom1973through1975. Mayo Clin Proc . 1977;52:549-545.
- 133. FardellaCE,PintoM,MossoL,Gómez-SánchezC,JalilJ,Montero J. Genetic study of patients with dexamethasone-suppressible aldosteronismwithoutthechimericCYP11B1/CYP11B2gene. J Clin Endocrinol Metab . 2001;86:4805-4807.
- 169. Jacobsen NE, Campbell JB, Hobart MG. Laparoscopic versus openadrenalectomyforsurgicaladrenaldisease. CanJUrol . 2003; 10:1995-1999.
Cited by
Items 801–900 of 1,002
Kline, G. A., So, B., Campbell, D. J. T., Chin, A., Harvey, A. M., Venos, E., Pasieka, J. L., & Leung, A. A. C. (2021) · Clinical Endocrinology · doi:10.1111/cen.14546 · Cited by 16
Song, Y., Yang, J., Shen, H., Ng, E., Fuller, P. J., Feng, Z., Hu, J., Ma, L., Yang, Y., Du, Z., et al. (2022) · Journal of Hypertension · doi:10.1097/hjh.0000000000003197 · Cited by 17
“5 ng/dl (235 pmol/l) in the seated position [25]; PAC greater than 6ng/dl (166 pmol/l) on the fourth day of fludrocortisone administration [1].”
BackgroundMethodInfluentialRadiofrequency ablation treatment for aldosterone-producing adenomas
Sacks, B. A., Sacks, A. C., & Faintuch, S. (2017) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000329 · Cited by 16
Vorselaars, W. M. C. M., Valk, G. D., Vriens, M. R., Westerink, J., & Spiering, W. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001718 · Cited by 19
“In accordance to the ESG, a PAC greater than 280 pmol/l measured after 2 l saline infusion in 4 h is used as reference standard for diagnosing primary aldosteronism [11].”
InfluentialBarros, E., Carotti, V., Vries, C. R. S., Witsel, F., Arntz, O. J., van de Loo, F. A. J., Carvajal, C. A., Bindels, R. J. M., Hoenderop, J. G. J., & Rigalli, J. P. (2021) · The FASEB Journal · doi:10.1096/fj.202002559r · Cited by 17
Chen, Y., Xu, T., Xu, J., Zhu, L., Li, Y., & Wang, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.770711 · Cited by 16
Adrenal venous sampling in primary aldosteronism: lessons from over 600 single-operator procedures
So, B., Leung, A. A. C., Chin, A., & Kline, G. A. (2021) · Clinical Radiology · doi:10.1016/j.crad.2021.11.005 · Cited by 16
Neutrophil gelatinase–associated lipocalin as an immunomodulator in endocrine hypertension
Araos, P. A., & Amador, C. A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1006790 · Cited by 16
“Current guidelines recommend using the Aldo to renin ratio for PA analysis (14).”
MethodAldosterone-to-renin ratio (ARR) as a screening tool for primary aldosteronism (PA)
Lin, C., Lin, C., Chung, M., Hung, C., Tseng, F., Er, L., Hou, C. J., Lin, Y., Wu, V., Cheng, H., et al. (2023) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2023.04.019 · Cited by 16
Ho, W.-Y., Hsiao, C.-C., Wu, P., Chen, J., Tu, Y., Wu, V., & Chen, J. (2024) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223241239775 · Cited by 16
Caroccia, B., Lenzini, L., Ceolotto, G., Gioco, F., Benetti, A., Giannella, A., Ajjour, H., Galuppini, F., Pennelli, G., Seccia, T. M., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae411 · Cited by 16
“All were unequivocally diagnosed with PA according to current specific guidelines (19-21).”
Serum Steroid Profiling in the Diagnosis of Adrenocortical Carcinoma: A Prospective Cohort Study
Yu, K., Athimulam, S., Saini, J., Kaur, R. J., Xue, Q., McKenzie, T. J., Singh, R. J., Grebe, S. K. G., & Bancos, I. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae604 · Cited by 16
Zuo, R. M., Liu, S., Ren, X., Li, W., Xia, Z., Xu, L., & Pang, H. (2024) · Endocrine · doi:10.1007/s12020-024-04024-7 · Cited by 17
“Less than 10% of PA patients ful fi ll the 2016 Endo-crine Society guidelines, which allow young patients with unilateral adenomas and substantial PA symptoms to forego AVS in favor of immediate surgery [9, 12].”
Presentation and management of patients with adrenal masses: a large tertiary centre experience
Suntornlohanakul, O., Mandal, S., Saha, P., Saygılı, E. S., Asia, M. F., Arlt, W., Elhassan, Y., Prete, A., & Ronchi, C. L. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae131 · Cited by 16
Salle, S. P., Brown, J. M., Mahrokhian, S., Hanna, I., Honzel, B., Tsai, L. C., Newman, A. J., Wang, T. J., & Vaidya, A. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf129 · Cited by 16
Tumor suppressive Ca2+ signaling is driven by IP3 receptor fitness
Bultynck, G., & Campanella, M. (2017) · Cell Stress · doi:10.15698/cst2017.11.109 · Cited by 15
Urinary Metabolic Signature of Primary Aldosteronism: Gender and Subtype‐Specific Alterations
Lana, A., Alexander, K., Castagna, A., D’Alessandro, A., Morandini, F., Pizzolo, F., Zorzi, F., Mulatero, P., Zolla, L., & Olivieri, O. (2018) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201800049 · Cited by 18
Li, T., Ma, Y., Zhang, Y., Liu, Y., Fu, T., Zhang, R., Kang, K., Yang, Y., Wang, L., Jiang, Y., et al. (2019) · International Journal of Hypertension · doi:10.1155/2019/2195796 · Cited by 15
Prejbisz, A., Dobrowolski, P., Kosiński, P., Bomba-Opon, D. A., Adamczak, M., Bekiesińska‐Figatowska, M., Kądziela, J., Konopka, A., Kostka-Jeziorny, K., Kurnatowska, I., et al. (2019) · Arterial Hypertension · doi:10.5603/ah.a2019.0011 · Cited by 16
Zein, R. M. E., Soria, A. H., Dzib, J. F. G., Rickard, A. J., Fernandes-Rosa, F. L., Samson-Couterie, B., Giscos-Douriez, I., Rocha, A., Poglitsch, M., Gómez-Sánchez, C. E., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-50988-2 · Cited by 15
Suntornlohanakul, O., Soonthornpun, S., Srisintorn, W., Murray, R. D., & Kietsiriroje, N. (2020) · Clinical Endocrinology · doi:10.1111/cen.14210 · Cited by 15
Wan, J., Ran, F., Xia, S., Hou, J., Wang, D., Liu, S., Yang, Y., Zhou, P., & Wang, P. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00685-x · Cited by 15
Volumetric evaluation of CT images of adrenal glands in primary aldosteronism
Velema, M. S., Canu, L., Dekkers, T., Hermus, A. R. M. M., Timmers, H. J. L. M., Kool, L. J. S., Groenewoud, H., Jacobs, C., Deinum, J., for the SPARTACUS Investigators, et al. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01540-5 · Cited by 16
Pauzi, F. A., & Azizan, E. A. B. A. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.631848 · Cited by 16
Guo, R., Li, Y., & Li, X. (2021) · Updates in Surgery · doi:10.1007/s13304-021-01069-5 · Cited by 15
A GLP-1 Receptor Agonist Inhibits Aldosterone Release in Healthy Volunteers
Sedman, T., Volke, V., Heinla, K., & Vasar, E. (2021) · Hormone and Metabolic Research · doi:10.1055/a-1498-7098 · Cited by 16
“The saline infusion test is widely used for confirming the diagnosis of primary aldosteronism but has important limitations [34].”
Adrenal venous sampling in the diagnostic workup of primary aldosteronism
Betz, M. J., & Zech, C. J. (2021) · British Journal of Radiology · doi:10.1259/bjr.20210311 · Cited by 15
Manosroi, W., Atthakomol, P., Watanawittawas, P., & Buranapin, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.870047 · Cited by 17
Ojeda, C. M., Santos, V. G. D., Álvaro, J. L., Ruz‐Caracuel, I., Pian, H. G., Dehesa, A. S., Revilla, F. J. B., & Castro, M. A. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01836-0 · Cited by 15
Lin, W., Gan, W., Feng, P., Zhong, L., Yao, Z., Chen, P., He, W., & Yu, N. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.882148 · Cited by 15
Clinical and biochemical predictors and predictive model of primary aldosteronism
Manosroi, W., Tacharearnmuang, N., & Atthakomol, P. (2022) · PLoS ONE · doi:10.1371/journal.pone.0272049 · Cited by 15
“These factors can lead to relatively high ARR and may result in an increased diagnostic prevalence of PA [13– 15].”
BackgroundMethodInfluentialPrevalence of Primary Aldosteronism in Newly Diagnosed Hypertensive Patients in Primary Care
Asbach, E., Kellnar, A., Bekeran, M., Schelling, J., Bidlingmaier, M., & Reincke, M. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1938-4242 · Cited by 16
“The 2016 Endocrine Society guideline recommends screening for PA in all hypertensive patients with a high risk of PA, which applies to more than half of the hypertensive popu lation [3].”
BackgroundSelf-citationStölting, G., Dinh, H. A., Volkert, M., Hellmig, N., Schewe, J., Hennicke, L., Seidel, E., Oberacher, H., Zhang, J., Lifton, R. P., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.162468 · Cited by 15
“Cacna1d Ile772Met/+ mice had high aldosterone levels that remained elevated (along with elevated Cyp11b2 levels) after a high-salt diet, confirming PA (41).”
BackgroundGenerating method-specific Reference Ranges – A harmonious outcome?
Lee, G. R., Griffin, A., Halton, K., & Fitzgibbon, M. C. (2017) · Practical Laboratory Medicine · doi:10.1016/j.plabm.2017.06.001 · Cited by 15
Okamoto, R., Taniguchi, M., Onishi, Y., Kumagai, N., Uraki, J., Fujimoto, N., Fujii, E., Yano, Y., Ogura, T., & Ito, M. (2018) · Hypertension Research · doi:10.1038/s41440-018-0126-1 · Cited by 15
Pizon, T., Rajzer, M., Wojciechowska, W., Wach-Pizoń, M., Dróżdż, T., Wróbel, K., Gruszka, K., Rojek, M., Kameczura, T., Jurczyszyn, A. J., et al. (2018) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320318810022 · Cited by 15
Diagnostic Accuracy of the Aldosterone–to–Active Renin Ratio for Detecting Primary Aldosteronism
Pilz, S., Keppel, M. H., Trummer, C., Theiler‐Schwetz, V., Pandis, M., Borzan, V., Pittrof, M., Obermayer-Pietsch, B. M., Grübler, M. R., Verheyen, N., et al. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00145 · Cited by 16
“The recommended screening test for PA is determination of the aldosterone-to-renin ratio because it reflects the degree of aldosterone synthesis that is autonomous with regard to renin [1, 4].”
BackgroundMethodInfluentialPrimary Aldosteronism: Where Are We Now? Where to from Here?
Funder, J. W. (2020) · Hormone and Metabolic Research · doi:10.1055/a-1120-8623 · Cited by 18
“The current guidelines on screening – for 50 % [37] to 100 % [41] of hypertensive patients – present a massive discouragement for general practitioners to whom a hypertensive patient presents.”
BackgroundSelf-citationZhang, C., Wu, L., Jiang, L., Su, T., Zhou, W., Zhong, X., Xie, J., Sun, F., Zhu, Y., Jiang, Y., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.01.007 · Cited by 16
Unilateral Disease Is Common in Patients With Primary Aldosteronism Without Adrenal Nodules
Sam, D., Kline, G. A., So, B., Przybojewski, S. J., & Leung, A. A. C. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.05.013 · Cited by 16
Three-year follow up of adrenal incidentalomas in a New Zealand centre
Goh, Z., Phillips, I., Hunt, P. J., Soule, S., & Cawood, T. J. (2020) · Internal Medicine Journal · doi:10.1111/imj.14332 · Cited by 14
Katsuragawa, S., Le, M. V., Fuller, P. J., & Yang, J. J. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00263-3 · Cited by 16
Unmasking Hormonal Mechanisms of Hypertension in Obesity
Salle, S. P., Tsai, C., Newman, A. J., Chan, J. M., Milks, J., Adler, G. K., Ferrebus, A., Hanna, I., Mahrokhian, S., Pitt, B., et al. (2026) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2026.101526 · Cited by 15
Carvajal, C. A., Tapia-Castillo, A., Pérez, J. A., & Fardella, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.768734 · Cited by 15
Long-term blood pressure outcomes of laparoscopic adrenalectomy in trHTN patients
Deng, Y., Wang, H., Guo, X., Jiang, S., & Cai, J. (2021) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2021-0005 · Cited by 19
Teixeira, J. P., Inglés, D. P., Barton, J., Dean, J. T., García, P., Kunkel, S. J., Sarangarm, P., Weiss, N. K., Schaich, C. L., Busse, L. W., et al. (2024) · Trials · doi:10.1186/s13063-024-07995-0 · Cited by 14
Jiang, Y., Zhou, L., Zhang, C., Su, T., Jiang, L., Zhou, W., Zhong, X., Wu, L., & Wang, W. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1369582 · Cited by 14
Guo, C., Zhang, G., Wu, C., Yi, L., Wang, Y., & Yang, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116521 · Cited by 15
Prevalence and Characteristics of Low-renin Hypertension in a Primary Care Population
Shah, S. S., Libianto, R., Gwini, S. M., Russell, G., Young, M. J., Fuller, P. J., & Yang, J. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae113 · Cited by 16
“Over the years, analytical methods for measuring renin have evolved; the direct renin concentration immunoassay is accessible with a quick turnaround time at most major pathology laboratories and thus has largely superseded plasma renin activity assays [11].”
BackgroundMethodInfluentialImpact of primary aldosteronism on kidney function: results from the SPAIN-ALDO registry
Castro, M. A., Fano, M. P., Boillos, M. G., Corrales, E. P., Rojas‐Marcos, P. M., Cano, A. M. G., Ruiz-Sánchez, J. G., Vicente, A., Hoyos, E. G., Casteràs, A., et al. (2024) · Journal of Hypertension · doi:10.1097/hjh.0000000000003813 · Cited by 14
Aldosterone-induced salt appetite requires HSD2 neurons
Gasparini, S., Peltekian, L., McDonough, M. C., Mitchell, C. J. A., Hefti, M. M., Resch, J. M., & Geerling, J. C. (2024) · JCI Insight · doi:10.1172/jci.insight.175087 · Cited by 16
“Relative to others with hypertension, patients with aldosteronism suffer from stroke, myocardial infarction, atrial fibrillation, and heart failure at several-fold higher rates (5–7) and have moderately elevated rates of diabetes and dementia (8–10).”
Aldosterone in the brain and cognition: knowns and unknowns
Nieckarz, A., Graff, B., Burnier, M., Marcinkowska, A. B., & Narkiewicz, K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1456211 · Cited by 16
Yoshida, Y., & Shibata, H. (2024) · Hypertension Research · doi:10.1038/s41440-024-01970-7 · Cited by 15
“However, IHA is often a relatively mild disease compared to APA, and based on most international guidelines IHA is generally treated with MRAs [3, 15, 16].”
Self-citationZuo, R., Liu, S., Ren, X., Li, W., Xia, Z., Xu, L., & Pang, H. (2025) · Clinical Endocrinology · doi:10.1111/cen.15204 · Cited by 14
Real-world outcomes of finerenone in primary aldosteronism
Uslar, T., Sanfuentes, B., Muñoz, I., Vaidya, A., & Baudrand, R. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf099 · Cited by 16
Inoue, K., Omura, M., Sugisawa, C., Tsurutani, Y., Saito, J., & Nishikawa, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18050948 · Cited by 14
“Primary aldosteronism (PA) is a major cause of secondary hypertension [1].”
BackgroundMethodEfficient screening of patients with aldosterone-producing adenoma using the ACTH stimulation test
Kita, T., Furukoji, E., Sakae, T., & Kitamura, K. (2019) · Hypertension Research · doi:10.1038/s41440-018-0191-5 · Cited by 15
Huang, C., Lee, B., Liu, K., Chang, Y., Wu, V., Lee, P., & Chang, C. (2020) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2020.04.016 · Cited by 14
Zhang, S.-L., Gao, J., Guo, Y., Feng, Q., Tang, J., Yan, L., Wang, J., Cheng, H., & Liu, P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.547356 · Cited by 15
Prediction of hyperaldosteronism subtypes when adrenal vein sampling is unilaterally successful
Burrello, J., Burrello, A., Pieroni, J., Sconfienza, E., Forestiero, V., Amongero, M., Rossato, D., Veglio, F., Williams, T. A., Monticone, S., et al. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0656 · Cited by 14
Parasiliti‐Caprino, M., Bioletto, F., Ceccato, F., Lopez, C., Bollati, M., Voltan, G., Rossato, D., Giraudo, G., Scaroni, C. M., Ghigo, E., et al. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002700 · Cited by 15
“Plasma aldosterone concentration (PAC), plasma renin activity (PRA) and PAC after saline infusion test (SIT) were determined in all patients after the replacement of interfering drugs, according to ES guidelines [1].”
MethodQuality of Life of Primary Aldosteronism Patients by Mineralocorticoid Receptor Antagonists
Yoshida, Y., Yoshida, R., Shibuta, K., Ozeki, Y., Okamoto, M., Gotoh, K., Masaki, T., & Shibata, H. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab020 · Cited by 14
Self-citationProperly Collected Plasma Metanephrines Excludes PPGL After False-Positive Screening Tests
Kline, G. A., Boyd, J. M., Polzin, B., Harvey, A. M., Pasieka, J. L., Sadrzadeh, H. S. M., & Leung, A. A. C. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab241 · Cited by 14
Hu, J., Chen, J., Cheng, Q., Jing, Y., Yang, J., Du, Z., Song, Y., Ma, L., Yang, Y., Luo, T., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.784706 · Cited by 14
Diagnóstico del hiperaldosteronismo primario
Castro, M. A., & Ramírez, P. A. P. (2021) · Medicina Clínica · doi:10.1016/j.medcli.2021.10.012 · Cited by 16
“Estas se deben realizar en todos los pacientes con test de cribado positivo, salvo en aquellos pacientes con un HAP manifiesto, con niveles de aldosterona plasmática > 20 ng/dL, con-centraciones de renina suprimida e hipopotasemia espontánea, lo cual confirma el diagnóstico sin necesidad de test de…”
BackgroundImpact of Intraprocedural Sedation on Adrenal Vein Sampling without Corticotropin Stimulation
Yang, J., Libianto, R., Lau, K. K., Doery, J. C. G., Wan, K. L., Chee, N. Y. N., Shen, J., Fuller, P. J., & Chong, W. (2022) · Radiology · doi:10.1148/radiol.212627 · Cited by 14
Nomura, M., Kurihara, I., Itoh, H., Ichijo, T., Katabami, T., Tsuiki, M., Wada, N., Yoneda, T., Sone, M., Oki, K., et al. (2022) · Hypertension Research · doi:10.1038/s41440-022-00960-x · Cited by 14
“Therefore, clinical guidelines recommend treatment with an MR antagonist (MRA) in cases in which patients with PA have bilateral PA or when they are unwilling or unable to undergo surgery [2].”
BackgroundSelf-citationIs the Adrenal Incidentaloma Functionally Active? An Approach-To-The-Patient-Based Review
Bernardi, S., Calabrò, V., Cavallaro, M., Lovriha, S., Eramo, R., Fabris, B., de Manzini, N., & Dobrinja, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11144064 · Cited by 16
“Once the diagnosis of primary aldosteronism has been made, the evidence of an adrenal incidentaloma is not enough to surgically remove the nodule, except for patients aged <35 years, with spontaneous hypokalemia, marked aldosterone excess, and a unilateral adrenal lesion consistent with a cortical adenoma [14].”
BackgroundInfluentialQian, N., Xu, J., & Wang, Y. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9090300 · Cited by 15
“The current recommended treatment for PA mainly includes surgical adrenalectomy and medical treatment with mineralocorticoid receptor (MR) antagonists based on PA subtype classifications and patient preference [2].”
BackgroundMethodKobayashi, H., Nakamura, Y., Abe, M., Tanabe, A., Sone, M., Katabami, T., Kurihara, I., Ichijo, T., Tsuiki, M., Izawa, S., et al. (2023) · Endocrine Journal · doi:10.1507/endocrj.ej22-0585 · Cited by 14
Prevalence of primary aldosteronism among patients with type 2 diabetes
Tancredi, M., Johannsson, G., Eliasson, B., Eggertsen, R., Lindblad, U., Dahlqvist, S., Imberg, H., & Lind, M. (2017) · Clinical Endocrinology · doi:10.1111/cen.13370 · Cited by 14
“who were judged clinically indicated in line with guidelines (31) for diagnosis of PA were further evaluated.”
Grotevendt, A., Wallaschofski, H., Reincke, M., Adolf, C., Quinkler, M. O., Nauck, M. A., Hoffmann, W. U., Rettig, R., & Hannemann, A. (2017) · Endocrine · doi:10.1007/s12020-017-1348-8 · Cited by 14
Self-citationYamashita, T., Shimizu, S., Koyama, M., Ohno, K., Mita, T., Tobisawa, T., Takada, A., Togashi, N., Ohnuma, Y., Hasegawa, T., et al. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001511 · Cited by 15
“the ENDO and the Japanese Society of Hypertension (JSH) recommend selection of patient groups with a relatively high prevalence of primary aldosteronism, that is, those with moderate-to-severe hypertension, resistant hypertension, hypertension with adrenal incidentaloma, and hypokalemia [2,3].”
BackgroundMethodInfluentialCardiac magnetic resonance imaging of myocardial mass and fibrosis in primary aldosteronism
Grytaas, M. A., Sellevåg, K., Thordarson, H. B., Husebye, E. S., Løvås, K., & Larsen, T. H. (2018) · Endocrine Connections · doi:10.1530/ec-18-0039 · Cited by 16
Pharmacological and analytical interference in hormone assays for diagnosis of adrenal incidentaloma
Lopez, A.-G., Fraissinet, F., Lefèbvre, H., Brunel, V., & Ziegler, F. (2019) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.11.006 · Cited by 15
Utility of microcatheter in adrenal venous sampling for primary aldosteronism
Noda, Y., Goshima, S., Nagata, S., Kawada, H., Tanahashi, Y., Kato, T., Suwa, T., Kawai, N., Yabe, D., & Matsuo, M. (2020) · British Journal of Radiology · doi:10.1259/bjr.20190636 · Cited by 15
Huayllas, M. K. P., Sirineni, G. K. R., Smith, L. M., Gallagher, J. C., Singh, R., Netzel, B. C., & Kater, C. E. (2020) · American Journal of Roentgenology · doi:10.2214/ajr.19.21753 · Cited by 16
Kawashima, J., Araki, E., Naruse, M., Kurihara, I., Takahashi, K., Tamura, K., Kobayashi, H. H., Okamura, S., Miyauchi, S., Yamamoto, K. I., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa117 · Cited by 15
Sex Differences in Renal Outcomes After Medical Treatment for Bilateral Primary Aldosteronism
Nakamaru, R., Yamamoto, K. I., Akasaka, H., Rakugi, H., Kurihara, I., Yoneda, T., Ichijo, T., Katabami, T., Tsuiki, M., Wada, N., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.16449 · Cited by 15
“The results of the present study show that (1) the temporal reduction of eGFR was greater in women than in men over a 5-year period; (2) female sex was a significant predictor of increased annual decline in eGFR during the late phase in patients taking spironolactone but not in those taking eplerenone; (3) spironolact…”
ResultScreening for Primary Aldosteronism is Underutilized in Patients with Obstructive Sleep Apnea
Conroy, P. C., Hernandez, S., Graves, C. E., Menut, K. C., Pearlstein, S., Liu, C., Shen, W. T., Gosnell, J. E., Sosa, J. A., Roman, S. A., et al. (2021) · The American Journal of Medicine · doi:10.1016/j.amjmed.2021.07.041 · Cited by 15
Gan, L., Li, N., Heizhati, M., Lin, M., Zhu, Q., Yao, X., Wu, T., Wang, M., Luo, Q., Zhang, D., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1017177 · Cited by 15
An Abbreviated History of Aldosterone Metabolism, Current and Future Challenges
Gómez-Sánchez, C. E., & Gómez-Sánchez, E. P. (2023) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2054-1062 · Cited by 15
“Measurement of urinary aldosterone, which is mostly 18-oxo-glucuronide, on a high sodium diet is one of the recommended confirmatory tests for primary aldosteronism [73] and has also been used as a screening and confirmatory test for primary aldosteronism in patients with low renin hypertension [74].”
MethodPrimary aldosteronism associated with a germline variant in CACNA1H
Wulczyn, K. E., Perez‐Reyes, E., Nussbaum, R. L., & Park, M. (2019) · BMJ Case Reports · doi:10.1136/bcr-2018-229031 · Cited by 15
BiLiGe, W., Wang, C., Bao, J., Yu, D., Min, A., Hong, Z., Chen, X., Wang, M., & Wang, D. (2019) · Medicine · doi:10.1097/md.0000000000016611 · Cited by 14
“Primary aldosteronism was diagnosed in accordance with the US Endocrine Society guideline.([2]) The criteria used to establish the diagnosis were a history of hypertension (with or without hypokalemia) with biochemical evidence of hyperaldosteronism and suppressed plasma renin activity.”
BackgroundMethodInfluentialDenimal, D., & Duvillard, L. (2016) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563216645364 · Cited by 14
“The Endocrine Society guidelines for the management of primary aldosteronism (PA) have been updated recently.(1) As before, determination of the aldosterone-renin ratio (ARR) is advocated as the most reliable tool to screen for PA in high-risk groups of hypertensive patients; this recommendation echoes a widely held v…”
BackgroundMethodInfluentialSubclinical Primary Aldosteronism
Adlin, E. V. (2017) · Annals of Internal Medicine · doi:10.7326/m17-2237 · Cited by 15
“Patients with PA had higher risk for cardiovascular events than those with essential hypertension and similar blood pressure (6).”
BackgroundInfluentialZhao, G., Wang, T., Luan, Y., Xu, Y., Qin, N., Chen, W., & Wang, Q. (2025) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/14703203251351194 · Cited by 14
“62 The main manifestations of this disorder are hypertension, elevated serum ALD levels, and inhibition of circulating renin.”
Stölting, G., Vo, K. N. T., Haus, J., & Scholl, U. I. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01020-6 · Cited by 17
“The most common diagnosis in patients with elevated aldosterone-to-renin ratios is sporadic primary aldosteronism, which requires an extensive work-up 89 .”
InfluentialImpact of primary aldosteronism on renal function in patients with type 2 diabetes
Katsuragawa, S., Tsurutani, Y., Takiguchi, T., Saito, J., & Nishikawa, T. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13332 · Cited by 13
Subtype-specific Body Composition and Metabolic Risk in Patients With Primary Aldosteronism
Park, S. S., Ahn, C. H., Kim, S. W., Yoon, J. W., & Kim, J. H. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad520 · Cited by 14
The value of plasma metanephrine measurements during adrenal vein sampling
Carroll, R. W., Corley, B., Feltham, J., Whitfield, P., Park, W., Howard, R., Yssel, M., Phillips, I., Harper, S., & Yang, J. (2023) · Endocrine Connections · doi:10.1530/ec-23-0300 · Cited by 14
Ahn, C. H., Lee, Y., Kim, J. H., Oh, Y. L., Jung, K. C., & Jung, K. C. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad747 · Cited by 16
Target organ damage in untreated hypertensive patients with primary aldosteronism
Li, S., Huang, J., Zhu, C., Ng, M., Lin, Q., Wu, M., Liu, M., Wang, R., Cao, G., Chen, C., et al. (2024) · Journal of Clinical Hypertension · doi:10.1111/jch.14794 · Cited by 14
Decoding Monogenic Hypertension: A Review of Rare Hypertension Disorders
Gallegos, F. R., Delahunty, M., Hu, J., Yerigeri, S., Dev, V., Bhatt, G., & Raina, R. (2025) · American Journal of Hypertension · doi:10.1093/ajh/hpaf005 · Cited by 14
Diagnosis and Management of Primary Aldosteronism
(2011) · The Nurse Practitioner · doi:10.1097/01.npr.0000396310.36814.a6 · Cited by 13
Assessing the quality of guidelines for primary aldosteronism
Wu, J., Tian, W., Zhang, L., Zhang, J., & Zhou, B. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002046 · Cited by 13
“If surgical treatment was feasible and desired, most of the guidelines recommended considering an adrenal vein sampling (AVS) by an experienced radiologist to differentiate unilateral from bilateral adrenal disease.”
BackgroundMethodInfluentialUpdate: Selective adrenal venous sampling (AVS) – Indication, technique, and significance
Loberg, C., Antoch, G., Stegbauer, J., Dringenberg, T., Steuwe, A., Fürst, G., Haase, M., Rump, L. C., & Schimmöller, L. (2020) · RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren · doi:10.1055/a-1299-1878 · Cited by 17
“In order to calculate the selectivity index, one or more peripheral samples must be taken in consultation with the referring physician (endocrinologist, nephrologist); there is no standardized, generally applicable acceptance protocol [33].”
BackgroundMenut, K. C., Pearlstein, S., Conroy, P. C., Roman, S. A., Shen, W. T., Gosnell, J. E., Sosa, J. A., Duh, Q., & Suh, I. (2021) · Surgery · doi:10.1016/j.surg.2021.05.052 · Cited by 13
Memon, S. S., Lila, A. R., Barnabas, R., Goroshi, M., Sarathi, V., Shivane, V. K., Patil, V. A., Shah, N. S., & Bandgar, T. (2021) · Clinical Endocrinology · doi:10.1111/cen.14598 · Cited by 14
ATP1A1 Mutant in Aldosterone-Producing Adenoma Leads to Cell Proliferation
Kobuke, K., Oki, K., Gómez-Sánchez, C. E., Gómez-Sánchez, E. P., Itcho, K., Ohno, H., Nagano, G., Yoshii, Y., Baba, R., Kodama, T., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010981 · Cited by 13
“PA is mainly classified with aldosterone-producing adenoma (APA) and idiopathic hyperaldosteronism [4].”
Background
Metadata
- Authors
- Funder, J. W., Carey, R. M., Mantero, F., Murad, M. H., Reincke, M., Shibata, H., Stowasser, M., & Young, W. F.
- Affiliations
- Hudson Institute of Medical Research (AU)
- University of Virginia Health System (US)
- University of Padua (IT)
- Mayo Clinic (US)
- Klinikum of the Ludwig-Maximilians-University of Munich (M.R.), 80366 München, Bavaria, Germany
- Oita University (JP)
- The University of Queensland (AU)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2016-05-01
- Volume
- 101
- Issue
- 5
- Pages
- 1889-1916
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2290633895
- Semantic Scholar
- 36716f26ebd3b8e468f352d9132208c41e5688c0
- Cited by
- 2,925
- References
- 241
- Citations by year
- 2026: 236 · 2025: 397 · 2024: 315 · 2023: 329 · 2022: 329 · 2021: 315 · 2020: 293 · 2019: 238 · 2018: 200 · 2017: 188 · 2016: 72
- FWCI
- 233.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- primary aldosteronism, case finding, aldosterone-renin ratio, adrenal computed tomography, adrenal vein sampling, laparoscopic adrenalectomy, bilateral adrenal hyperplasia, mineralocorticoid receptor antagonists, hypertension, hypokalemia
- MeSH terms
- Adrenal Glands, Adrenalectomy, Aldosterone, Mineralocorticoid Receptor Antagonists, Humans, Hyperaldosteronism, Renin, Evidence-Based Medicine, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.